IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v6y2005i3p274-279.html
   My bibliography  Save this article

Reimbursement and clinical guidance for pharmaceuticals in Sweden

Author

Listed:
  • Anders Anell
  • Ulf Persson

Abstract

No abstract is available for this item.

Suggested Citation

  • Anders Anell & Ulf Persson, 2005. "Reimbursement and clinical guidance for pharmaceuticals in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 274-279, September.
    • Handle: RePEc:spr:eujhec:v:6:y:2005:i:3:p:274-279
    DOI: 10.1007/s10198-005-0301-6
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-005-0301-6
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-005-0301-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Anders Anell, 2004. "Priority setting for pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(1), pages 28-35, February.
    2. J. Lundkvist, 2002. "Pricing and reimbursement of drugs in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 3(1), pages 66-70, March.
    3. Joakim Ramsberg & Stefan Odeberg & Andreas Engström & Douglas Lundin, 2004. "Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(4), pages 351-356, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
    2. Brian Godman & Lars Gustafsson, 2013. "A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 79-82, February.
    3. Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
    4. David Granlund & Miyase Koksal-Ayhan, 2015. "Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 969-983, December.
    5. Hultkrantz, Lars & Svensson, Mikael, 2012. "A Comparison of Benefit Cost and Cost Utility Analysis in Practice: Divergent Policies in Sweden," Karlstad University Working Papers in Economics 1, Karlstad University, Department of Economics.
    6. Carlson, Josh J. & Sullivan, Sean D. & Garrison, Louis P. & Neumann, Peter J. & Veenstra, David L., 2010. "Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers," Health Policy, Elsevier, vol. 96(3), pages 179-190, August.
    7. Granlund, David & Köksal, Miyase Yesim, 2011. "Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?," HUI Working Papers 49, HUI Research.
    8. Adrian Levy & Craig Mitton & Karissa Johnston & Brian Harrigan & Andrew Briggs, 2010. "International Comparison of Comparative Effectiveness Research in Five Jurisdictions," PharmacoEconomics, Springer, vol. 28(10), pages 813-830, October.
    9. Michael Drummond, 2012. "Twenty Years of Using Economic Evaluations for Reimbursement Decisions. What Have We Achieved?," Working Papers 075cherp, Centre for Health Economics, University of York.
    10. Tania Stafinski & Devidas Menon & Deborah Marshall & Timothy Caulfield, 2011. "Societal Values in the Allocation of Healthcare Resources," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 4(4), pages 207-225, December.
    11. Wasem, Jürgen & Weegen, Lennart & Bauer, Cosima & Walendzik, Anke & Grande, Frederic & May, Uwe, 2015. "Regulatorische Handhabung der selektiven Erstattung von Arzneimitteln in den ausgewählten Ländern England, Niederlande, Frankreich und Schweden," IBES Diskussionsbeiträge 211, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).
    12. Lianne Barnieh & Fiona Clement & Anthony Harris & Marja Blom & Cam Donaldson & Scott Klarenbach & Don Husereau & Diane Lorenzetti & Braden Manns, 2014. "A Systematic Review of Cost-Sharing Strategies Used within Publicly-Funded Drug Plans in Member Countries of the Organisation for Economic Co-Operation and Development," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-10, March.
    13. Ulf Persson & Johanna Svensson & Billie Pettersson, 2012. "A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 217-225, July.
    14. Granlund, David & Yesim Köksal, Miyase, 2011. "Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals," Working Papers in Economics 496, University of Gothenburg, Department of Economics.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Gregory Merlo & Katie Page & Pauline Zardo & Nicholas Graves, 2019. "Applying an Implementation Framework to the Use of Evidence from Economic Evaluations in Making Healthcare Decisions," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 533-543, August.
    2. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    3. Martikainen, Jaana & Kivi, Ismo & Linnosmaa, Ismo, 2005. "European prices of newly launched reimbursable pharmaceuticals - a pilot study," Health Policy, Elsevier, vol. 74(3), pages 235-246, November.
    4. Morgan, Steve & McMahon, Meghan & Greyson, Devon, 2008. "Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia," Health Policy, Elsevier, vol. 87(2), pages 133-145, August.
    5. Gregory Merlo & Katie Page & Julie Ratcliffe & Kate Halton & Nicholas Graves, 2015. "Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake," Applied Health Economics and Health Policy, Springer, vol. 13(3), pages 303-309, June.
    6. Bergstrom, Gina & Karlberg, Ingvar, 2007. "Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective," Health Policy, Elsevier, vol. 81(2-3), pages 358-367, May.
    7. Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H., 2011. "A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention," Health Policy, Elsevier, vol. 101(3), pages 290-299, August.
    8. Granlund, David & Yesim Köksal, Miyase, 2011. "Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals," Working Papers in Economics 496, University of Gothenburg, Department of Economics.
    9. Dimitrova, V.; & Sameen, H.;, 2022. "Static regulation and technological change: Prescribing cost-effective treatments under financial constraints in the English NHS," Health, Econometrics and Data Group (HEDG) Working Papers 22/15, HEDG, c/o Department of Economics, University of York.
    10. Granlund, David & Yesim Köksal, Miyase, 2011. "EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals. What's blame? Derogation or perception?," Working Papers in Economics 499, University of Gothenburg, Department of Economics.
    11. Greß, Stefan & Klaucke, Lena & Kötting, Cosima & May, Uwe & Wasem, Jürgen, 2008. "Preisregulierung von verschreibungspflichtigen Arzneimitteln in der gesetzlichen Krankenversicherung nach dem GKV-Wettbewerbsstärkungsgesetz," IBES Diskussionsbeiträge 170, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).
    12. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.
    13. Granlund, David & Köksal, Miyase Yesim, 2011. "Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?," HUI Working Papers 49, HUI Research.
    14. Amani Thomas Mori & Eliangiringa Amos Kaale & Frida Ngalesoni & Ole Frithjof Norheim & Bjarne Robberstad, 2014. "The Role of Evidence in the Decision-Making Process of Selecting Essential Medicines in Developing Countries: The Case of Tanzania," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-10, January.
    15. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    16. Margreet Franken & Fredrik Nilsson & Frank Sandmann & Anthonius Boer & Marc Koopmanschap, 2013. "Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making," PharmacoEconomics, Springer, vol. 31(9), pages 781-797, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:6:y:2005:i:3:p:274-279. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.